Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04136756
Title NKTR-255 in Relapsed/Refractory Multiple Myeloma and Non Hodgkin Lymphoma and Combined With Daratumumab for Multiple Myeloma
Recruitment Enrolling by invitation
Gender both
Phase Phase I
Variant Requirements No
Sponsors Nektar Therapeutics

non-Hodgkin lymphoma

multiple myeloma



Daratumumab + NKTR-255

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.